Business Wire

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics

28.9.2020 13:00:00 EEST | Business Wire | Press release

Share

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005059/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

pci | bridge digital platform logo (Photo: Business Wire)

“At PCI, we are always looking to the future and could see the potential that technology and digital systems held for the pharmaceutical supply chain industry,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “Twelve months ago, we made the deliberate decision as an organization to invest more in this area, with the goal of enhancing client experiences, digitizing business processes and aligning our IT to scale as we grow. The launch of pci | bridge represents a key milestone achievement in our digital transformation journey. We believe our unique offering will simplify how our clients interact with us and create a leading-edge client experience.”

A direct connection between PCI and clients, the platform will make real-time information readily accessible to clients including inventory, production, distribution and shipping data, presented in organized, customizable formats. The platform also features a document repository where electronic paperwork can be stored and accessed in one place, and signatures secured on the platform.

“Having a fully functioning supply chain, whose foundation is built on digitally-enabled capabilities and technologies, means we can be more adept at moving resources, assets and inventory – quickly and effectively,” said Wayne Hull, Chief Digital and Technology Officer, PCI Pharma Services. “We are embracing new technologies at PCI because they improve client experiences, give greater visibility into the supply chain, and provide data insights to optimize efficiencies and mitigate risks.”

The technology behind pci | bridge will closely and very securely integrate PCI’s systems with those of clients so that the supply chain can be easily managed by both parties. One significant advantage is removing manual processes that are often time intensive for both sides.

“Seeking input from multiple customers to understand how we hope to use the platform and previewing iterations with us is invaluable in terms of structuring the tool so it can actually be helpful to our work,” said Wendy Xia, Senior Director, Head of Supply Chain at Agios Pharmaceuticals, a key PCI client who collaborated with the company on pci | bridge. “I am very excited about my team using pci | bridge because I think it will greatly increase productivity and efficiency on both ends.”

“The benefits I see of using pci | bridge is that is that it eliminates the need for clients to constantly reach out to the project teams for updates. Now, we will have that information at our fingertips and can instead focus on the bigger picture with PCI, such as what’s coming next,” added Kevin Gregorczyk, Director, Development Operations at eFFECTOR Therapeutics, another key PCI client who participated in the development process.

Post-launch, PCI will continue to evolve and update pci | bridge features to meet client needs.

To learn more about pci | bridge, click here.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bailey Watroba, WE Communications
bwatroba@we-worldwide.com / +1-617-234-4110

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 13:18:00 EEST | Press release

Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan. Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patie

Zoom Advances Its AI Strategy With a New Unified Context Layer That Helps Turn Meeting Conversations Into Completed Work22.10.2026 13:13:00 EEST | Press release

Today at its annual Zoomtopia customer conference, Zoom Communications, Inc. (NASDAQ: ZM), a leading AI-first platform for human connection, introduced a new Unified Context Layer and several new products with AI-powered capabilities. The new offerings are designed to help businesses transform rich meeting context into meaningful deliverables that help accelerate work outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021498160/en/ Business conversations drive critical decisions and build customer history every day. A customer interaction might start in a meeting, continue by phone, and carry on in chat threads. But when that context is scattered across applications, people, and AI agents lose the thread, and teams spend significant time piecing together what happened, when it happened, and what they should do about it. Zoom’s new Unified Context Layer helps close that gap by linking conversation history with releva

TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release

TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release

Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye